Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Inclusion Criteria

• •1. Age ≥ 18 years, gender is not limited;
• •2. Patients with lymphoma diagnosed by histopathology or cytology;
• •3. Patients requiring multi-cycle chemotherapy;
• •4. Planned chemotherapy regimen FN risk ≥ 20 % , or 10% \<FN risk \< 20% with high risk factors ; According to the judgment of the investigator, there is a risk of FN occurrence if G-CSF support is not accepted, PEG-rhG-CSF should be used prophylactically from the first cycle;
• •5. Physical status (KPS) score ≥ 70 points;
• •6. Expected Survival period of more than 3 months;
• •7. Normal bone marrow hematopoietic function (ANC ≥1.5×10\^9/L, PLT≥80×10\^9/L, Hb≥75g/L, WBC≥3.0×10\^9/L);
• •8. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5 times the upper limit of normal value, or≤5 times the upper limit of normal value when there is liver metastasis; total bilirubin (TBIL)≤2.5 times the upper limit of normal value; serum creatinine (Cr)≤2 times the upper limit of normal value;
• •9. Female patients of childbearing age must be negative in urine pregnancy test before treatment;
• •10. The testers (or their legal representatives/guardians) must sign an informed consent form.